vs
爵士制药（JAZZ）与越洋钻探（RIG）财务数据对比。点击上方公司名可切换其他公司
爵士制药的季度营收约是越洋钻探的1.1倍（$1.2B vs $1.0B），爵士制药净利率更高（17.0% vs 2.4%，领先14.6%），爵士制药同比增速更快（10.1% vs 9.6%），爵士制药自由现金流更多（$345.8M vs $321.0M），过去两年越洋钻探的营收复合增速更高（16.9% vs 15.2%）
爵士制药是一家全球性生物制药企业，核心业务聚焦肿瘤学与神经科学两大领域，2003年在美国加利福尼亚州成立，当前总部坐落于爱尔兰首都都柏林。
越洋钻探（Transocean Ltd.）是按营收计全球规模最大的海上钻探承包商，总部位于瑞士施泰因豪森，起源于美国，目前在加拿大、美国、挪威、英国、印度、巴西、新加坡等20个国家设有办事机构，业务覆盖全球主要海上油气开采区域。
JAZZ vs RIG — 直观对比
营收规模更大
JAZZ
是对方的1.1倍
$1.0B
营收增速更快
JAZZ
高出0.5%
9.6%
净利率更高
JAZZ
高出14.6%
2.4%
自由现金流更多
JAZZ
多$24.8M
$321.0M
两年增速更快
RIG
近两年复合增速
15.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.0B |
| 净利润 | $203.5M | $25.0M |
| 毛利率 | — | 42.0% |
| 营业利润率 | 21.2% | 23.0% |
| 净利率 | 17.0% | 2.4% |
| 营收同比 | 10.1% | 9.6% |
| 净利润同比 | 6.5% | 257.1% |
| 每股收益（稀释后） | $3.34 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAZZRIG
| Q4 25 | $1.2B | $1.0B | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.0B | $988.0M | ||
| Q1 25 | $897.8M | $906.0M | ||
| Q4 24 | $1.1B | $952.0M | ||
| Q3 24 | $1.1B | $948.0M | ||
| Q2 24 | $1.0B | $861.0M | ||
| Q1 24 | $902.0M | $763.0M |
净利润JAZZRIG
| Q4 25 | $203.5M | $25.0M | ||
| Q3 25 | $251.4M | $-1.9B | ||
| Q2 25 | $-718.5M | $-938.0M | ||
| Q1 25 | $-92.5M | $-79.0M | ||
| Q4 24 | $191.1M | $7.0M | ||
| Q3 24 | $215.1M | $-494.0M | ||
| Q2 24 | $168.6M | $-123.0M | ||
| Q1 24 | $-14.6M | $98.0M |
毛利率JAZZRIG
| Q4 25 | — | 42.0% | ||
| Q3 25 | — | 43.2% | ||
| Q2 25 | — | 39.4% | ||
| Q1 25 | — | 31.8% | ||
| Q4 24 | — | 39.2% | ||
| Q3 24 | — | 40.6% | ||
| Q2 24 | — | 38.0% | ||
| Q1 24 | — | 31.5% |
营业利润率JAZZRIG
| Q4 25 | 21.2% | 23.0% | ||
| Q3 25 | 5.1% | -163.1% | ||
| Q2 25 | -65.6% | -97.6% | ||
| Q1 25 | -6.2% | 7.1% | ||
| Q4 24 | 17.5% | 13.7% | ||
| Q3 24 | 24.7% | -51.2% | ||
| Q2 24 | 19.5% | -6.9% | ||
| Q1 24 | 7.3% | -0.4% |
净利率JAZZRIG
| Q4 25 | 17.0% | 2.4% | ||
| Q3 25 | 22.3% | -187.1% | ||
| Q2 25 | -68.7% | -94.9% | ||
| Q1 25 | -10.3% | -8.7% | ||
| Q4 24 | 17.6% | 0.7% | ||
| Q3 24 | 20.4% | -52.1% | ||
| Q2 24 | 16.5% | -14.3% | ||
| Q1 24 | -1.6% | 12.8% |
每股收益（稀释后）JAZZRIG
| Q4 25 | $3.34 | $0.13 | ||
| Q3 25 | $4.08 | $-2.00 | ||
| Q2 25 | $-11.74 | $-1.06 | ||
| Q1 25 | $-1.52 | $-0.11 | ||
| Q4 24 | $2.97 | $-0.14 | ||
| Q3 24 | $3.42 | $-0.58 | ||
| Q2 24 | $2.49 | $-0.15 | ||
| Q1 24 | $-0.23 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $620.0M |
| 总债务越低越好 | $5.4B | $5.2B |
| 股东权益账面价值 | $4.3B | $8.1B |
| 总资产 | $11.7B | $15.6B |
| 负债/权益比越低杠杆越低 | 1.24× | 0.64× |
8季度趋势，按日历期对齐
现金及短期投资JAZZRIG
| Q4 25 | $1.4B | $620.0M | ||
| Q3 25 | $1.3B | $833.0M | ||
| Q2 25 | $1.2B | $377.0M | ||
| Q1 25 | $1.9B | $263.0M | ||
| Q4 24 | $2.4B | $560.0M | ||
| Q3 24 | $2.2B | $435.0M | ||
| Q2 24 | $1.4B | $475.0M | ||
| Q1 24 | $1.4B | $446.0M |
总债务JAZZRIG
| Q4 25 | $5.4B | $5.2B | ||
| Q3 25 | $5.4B | $4.8B | ||
| Q2 25 | $5.4B | $5.9B | ||
| Q1 25 | $5.4B | $5.9B | ||
| Q4 24 | $6.1B | $6.2B | ||
| Q3 24 | $6.1B | $6.5B | ||
| Q2 24 | $5.7B | $6.8B | ||
| Q1 24 | $5.7B | $6.8B |
股东权益JAZZRIG
| Q4 25 | $4.3B | $8.1B | ||
| Q3 25 | $4.0B | $8.1B | ||
| Q2 25 | $3.7B | $9.4B | ||
| Q1 25 | $4.2B | $10.2B | ||
| Q4 24 | $4.1B | $10.3B | ||
| Q3 24 | $4.2B | $10.2B | ||
| Q2 24 | $3.8B | $10.7B | ||
| Q1 24 | $3.7B | $10.5B |
总资产JAZZRIG
| Q4 25 | $11.7B | $15.6B | ||
| Q3 25 | $11.4B | $16.2B | ||
| Q2 25 | $10.9B | $17.8B | ||
| Q1 25 | $11.5B | $19.0B | ||
| Q4 24 | $12.0B | $19.4B | ||
| Q3 24 | $12.3B | $19.5B | ||
| Q2 24 | $11.4B | $20.3B | ||
| Q1 24 | $11.3B | $19.9B |
负债/权益比JAZZRIG
| Q4 25 | 1.24× | 0.64× | ||
| Q3 25 | 1.35× | 0.60× | ||
| Q2 25 | 1.45× | 0.63× | ||
| Q1 25 | 1.29× | 0.58× | ||
| Q4 24 | 1.49× | 0.60× | ||
| Q3 24 | 1.47× | 0.64× | ||
| Q2 24 | 1.52× | 0.63× | ||
| Q1 24 | 1.54× | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $362.5M | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $345.8M | $321.0M |
| 自由现金流率自由现金流/营收 | 28.9% | 30.8% |
| 资本支出强度资本支出/营收 | 1.4% | 2.7% |
| 现金转化率经营现金流/净利润 | 1.78× | 13.96× |
| 过去12个月自由现金流最近4个季度 | $1.3B | $626.0M |
8季度趋势，按日历期对齐
经营现金流JAZZRIG
| Q4 25 | $362.5M | $349.0M | ||
| Q3 25 | $474.6M | $246.0M | ||
| Q2 25 | $88.9M | $128.0M | ||
| Q1 25 | $429.8M | $26.0M | ||
| Q4 24 | $398.6M | $206.0M | ||
| Q3 24 | $398.7M | $194.0M | ||
| Q2 24 | $331.4M | $133.0M | ||
| Q1 24 | $267.2M | $-86.0M |
自由现金流JAZZRIG
| Q4 25 | $345.8M | $321.0M | ||
| Q3 25 | $459.4M | $235.0M | ||
| Q2 25 | $75.9M | $104.0M | ||
| Q1 25 | $415.9M | $-34.0M | ||
| Q4 24 | $385.3M | $177.0M | ||
| Q3 24 | $388.0M | $136.0M | ||
| Q2 24 | $324.3M | $49.0M | ||
| Q1 24 | $260.3M | $-169.0M |
自由现金流率JAZZRIG
| Q4 25 | 28.9% | 30.8% | ||
| Q3 25 | 40.8% | 22.9% | ||
| Q2 25 | 7.3% | 10.5% | ||
| Q1 25 | 46.3% | -3.8% | ||
| Q4 24 | 35.4% | 18.6% | ||
| Q3 24 | 36.8% | 14.3% | ||
| Q2 24 | 31.7% | 5.7% | ||
| Q1 24 | 28.9% | -22.1% |
资本支出强度JAZZRIG
| Q4 25 | 1.4% | 2.7% | ||
| Q3 25 | 1.3% | 1.1% | ||
| Q2 25 | 1.2% | 2.4% | ||
| Q1 25 | 1.5% | 6.6% | ||
| Q4 24 | 1.2% | 3.0% | ||
| Q3 24 | 1.0% | 6.1% | ||
| Q2 24 | 0.7% | 9.8% | ||
| Q1 24 | 0.8% | 10.9% |
现金转化率JAZZRIG
| Q4 25 | 1.78× | 13.96× | ||
| Q3 25 | 1.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.09× | 29.43× | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.97× | — | ||
| Q1 24 | — | -0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
RIG
| Ultra Deepwater Floaters | $433.0M | 42% |
| BR | $236.0M | 23% |
| Other Geographical | $211.0M | 20% |
| Harsh Environment Floaters | $163.0M | 16% |
